Home Metabolism -Proteases PCSK9

PCSK9

Metabolism

Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR Carbonic Anhydrase Hydroxylase Liver X Receptor FAAH Acyltransferase Dehydrogenase Phosphorylase PPAR CYP17 CETP FXR HMG-CoA Reductase Transferase IDO/TDO Retinoid Receptor Casein Kinase NAMPT phosphatase Lipase Lipoxygenase Thioredoxin Decarboxylase Vitamin Serine/threonin kinase LDL Fatty Acid Synthase FOX Glycogen synthesis PKM Glycolysis HDL Carbohydrate Metabolism ATP-citrate lyase Acetyl-CoA carboxylase CYP450 PCSK9 Leukotriene PDHK PGC-1α ROR FABP Peroxidases Aldose Reductase Xanthine Oxidase THR Epoxide Hydrolase PEP GTPCH FAO PAI-1 LDH SCD PREP CPSase Mannosidase Thioredoxin Reductase SGK FTase γGCS CPT SREBP Mitochondrial Metabolism PARG Glucosylceramide Synthase Catalase 3-MST Serine hydrolase CAR glucocerebrosidase Mitochondrial pyruvate carrier GOT SHIP SOD LCN Endogenous Metabolite ATGL NMT Aconitase AGEs Amino Acids and Derivatives Amylase Drug Metabolite Glucokinase Glucosidase glycosidase GSNOR GST Hexokinase Isocitrate Dehydrogenase (IDH) Lipid Liposome LPL Receptor MAGL NEDD4-1 NPC1L1 PGK1 Reductase stilbene oxidase UGT
  • All (6)
  • PCSK9 Inhibitors (5)
  • PCSK9 Antagonist (1)
  • New PCSK9 Products
Cat.No. Product Name Information Product Use Citations Product Validations
S7976 SBC-115076 SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.
Cancers (Basel), 2024, 16(4)713
Front Med (Lausanne), 2024, 11:1284199
Front Med (Lausanne), 2024, 11:1509168
E4629New AZD0780 AZD0780 (Laroprovstat, Pcsk9-IN-12) is an orally potent inhibitor of PCSK9 with a Kd value of <200 nM. It directly binds to PCSK9, blocks its function, and significantly reduces LDL cholesterol levels, making it useful for dyslipidemia research.
S8420 R-IMPP R-IMPP is an inhibitor of PCSK9 secretion, half maximal inhibitory concentration [IC50] = 4.8 μM.
S0118 SBC-110736 SBC-110736 is an inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) that lowers cholesterol levels in mice.
E0116 PF-06446846 hydrochloride PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells.
S0849 PF-06446846 PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. This compound selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region.
E4629New AZD0780 AZD0780 (Laroprovstat, Pcsk9-IN-12) is an orally potent inhibitor of PCSK9 with a Kd value of <200 nM. It directly binds to PCSK9, blocks its function, and significantly reduces LDL cholesterol levels, making it useful for dyslipidemia research.
S8420 R-IMPP R-IMPP is an inhibitor of PCSK9 secretion, half maximal inhibitory concentration [IC50] = 4.8 μM.
S0118 SBC-110736 SBC-110736 is an inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) that lowers cholesterol levels in mice.
E0116 PF-06446846 hydrochloride PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells.
S0849 PF-06446846 PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. This compound selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region.
S7976 SBC-115076 SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.
Cancers (Basel), 2024, 16(4)713
Front Med (Lausanne), 2024, 11:1284199
Front Med (Lausanne), 2024, 11:1509168
E4629New AZD0780 AZD0780 (Laroprovstat, Pcsk9-IN-12) is an orally potent inhibitor of PCSK9 with a Kd value of <200 nM. It directly binds to PCSK9, blocks its function, and significantly reduces LDL cholesterol levels, making it useful for dyslipidemia research.